Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now

Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association’s 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with elevated LDL-C but no history of heart attack or stroke, the addition of Repatha to existing lipid-lowering therapies reduced the risk of major adverse cardiovascular events by 29% compared to a placebo.

Dr. Jay Bradner, Amgen’s EVP of Research and Development, emphasized that early and intensive LDL-C reduction is vital for preventing cardiovascular events in this vulnerable population. The findings held consistent regardless of whether patients were concurrently using SGLT2 inhibitors or GLP-1 receptor agonists, underscoring the necessity of managing multiple risk factors, particularly uncontrolled LDL-C, in individuals living with diabetes.

Beyond the VESALIUS-CV results, Amgen shared real-world evidence identifying significant treatment gaps in current diabetes and obesity care. Studies indicated that low treatment persistence and adherence to GLP-1 therapies often lead to less effective outcomes in clinical practice than those observed in trials. Amgen Inc. (NASDAQ:AMGN) noted that these findings highlight a critical need for new care strategies and treatment approaches that help patients sustain therapy to achieve long-term metabolic health goals.

Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.